Internal Medicine, Hematology & Oncology · Kalamazoo, MI
NPI
1982884128
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
805 John Street
Kalamazoo, MI, 49001
Phone (269) 286-7170
Groups this clinician bills Medicare through
Medicare paid, 2024
$53K
786 services
Medicare patients, 2024
376
Average age 75
Drug cost, 2024
$10.7M
2,506 prescriptions
Company payments, 2025
$405
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohammad Omaira was code 99214 (office e&m - established), 318 times for 139 patients. In total Mohammad Omaira billed 786 services in 12 codes, and Medicare paid $53K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-01-28.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 318 | 139 | $67.95 | $22K |
| 99213 Office E&M - Established | Facility | 227 | 187 | $41.91 | $9,513 |
| 99215 Office E&M - Established | Facility | 98 | 53 | $106.25 | $10K |
| 99204 Office E&M - New | Facility | 48 | 48 | $78.17 | $3,752 |
| 99233 Hospital E&M - Subsequent | Facility | 38 | 21 | $87.95 | $3,342 |
| 99205 Office E&M - New | Facility | 16 | 16 | $131.55 | $2,105 |
| 99213 Office E&M - Established | Office | 15 | 12 | $55.28 | $829 |
By year: 2022 $57K for 871 services; 2023 $57K for 857 services; 2024 $53K for 786 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohammad Omaira prescribed most often to Medicare patients was Acyclovir, with 261 prescriptions and refills. In total Mohammad Omaira wrote 2,506 Medicare prescriptions that cost $10.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 261 | 407 | 64 | $4,639 |
| Hydroxyurea Generic | 235 | 488 | 55 | $7,047 |
| Eliquis Apixaban | 192 | 338 | 46 | $191K |
| Venclexta Venetoclax | 134 | 135 | 24 | $1.1M |
| Lenalidomide Generic | 128 | 128 | 27 | $1.8M |
| Revlimid Lenalidomide | 118 | 118 | 26 | $1.9M |
| Dexamethasone Generic | 97 | 155 | 36 | $1,521 |
| Jakafi Ruxolitinib Phosphate | 89 | 89 | Under 11 | $1.7M |
| Imbruvica Ibrutinib | 77 | 77 | Under 11 | $1.1M |
| Pomalyst Pomalidomide | 63 | 63 | Under 11 | $1.4M |
| Gabapentin Generic | 53 | 57 | Under 11 | $402 |
| Prednisone Generic | 51 | 78 | 21 | $487 |
| Potassium Chloride Generic | 44 | 54 | 15 | $636 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 43 | 43 | 14 | $534 |
| Allopurinol Generic | 41 | 45 | 26 | $181 |
Brand drugs: - claims; generic drugs: 1,642 claims; opioid claims: 145.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohammad Omaira $405 ($405 in general payments such as food, travel and fees) from 12 companies. The largest payer was Novartis Pharmaceuticals Corporation with $113.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 5 | $113 |
| Genentech USA, Inc. ROG.SW | 4 | $84.91 |
| Eisai Inc. 4523.T | 1 | $34.72 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $27.23 |
| Merck Sharp & Dohme LLC MRK | 1 | $26.12 |
| Karyopharm Therapeutics Inc. KPTI | 1 | $23.59 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 1 | $23.4 |
| GlaxoSmithKline, LLC. GSK | 1 | $22.21 |
| Janssen Biotech, Inc. JNJ | 1 | $19.24 |
| Syndax Pharmaceuticals, Inc. SNDX | 1 | $16.51 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.